A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
← catalyst calendarNCT07218380 · readout ≤ 1,169 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
450estimated
Sites
289
Countries
Australia, Brazil, Canada +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-12 | actual | When the study began enrolling |
| Primary completion | Oct 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Transitional Cell
- Urinary Bladder Neoplasms
- Neoplasm Metastasis
Interventions
- Drug: Vepugratinib
- Other: Placebo
- Drug: EV
- Drug: Pembrolizumab
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab
measured From baseline up to 90 months
Safety Lead-in: Overall Response Rate (ORR)
measured From baseline up to 90 months
Progression-free Survival (PFS)
measured Baseline to Study Completion (estimated as 6 years)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed